Greater survival benefit shown in men with early and less aggressive mCRPC treated with Zytiga® plus prednisone
Janssen announced that data from a post-hoc analysis of the Phase III COU-AA-302 trial showed that ZYTIGA® plus prednisone provided an 11.8 months overall survival benefit, compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology Patient care advanced prostate cancer COU-AA-302 trial European Association of Urology Latest News mCRPC Zytiga Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Prednisone | Prostate Cancer | Urology & Nephrology